ConductScience.org, home
Papers
API referenceFor AI assistants

Paper · 39296459

Salvage lung resection after immunotherapy is feasible and safe.

Nemeth A and 9 others. JTCVS Open, 2024. Cited by 6 papers, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Download JSON
Cite this record

ConductScience Library. Salvage lung resection after immunotherapy is feasible and safe. Papers, record 39296459. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39296459

On this page

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Salvage lung resection after immunotherapy is feasible and safe.
PubMed
Journal
JTCVS Open
PubMed
Year
2024
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
6
iCite
Relative citation ratio, by iCite
0.81, provisional
iCite
Revised in PubMed
2024-09-20
PubMed

Authors10

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Nemeth AAttila
2Canavan MEMaureen E
3Zhan PLPeter L
4Udelsman BVBrooks V
5Ely SSora
6Wigle DADennis A
7Martin LLinda
8Jeffrey Yang CFChi-Fu
9Boffa DJDaniel J
10Dhanasopon APAndrew P

Source PubMed

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

Grants0

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

None in this release.

Trials0

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

None in this release.

Comments and corrections0

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

None in this release.

References27

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
128,823,336Salvage Surgery After Definitive Chemoradiotherapy for Non-small Cell Lung Cancer.Semin Thorac Cardiovasc Surg2017https://conductscience.org/library/papers/28823336PubMed
226,781,697Should salvage surgery be considered for local recurrence after definitive chemoradiation in locally advanced non-small cell lung cancer?J Cardiothorac Surg2016https://conductscience.org/library/papers/26781697PubMed
333,689,225Neoadjuvant immunotherapy for non-small cell lung cancer: State of the art.Cancer Commun (Lond)2021https://conductscience.org/library/papers/33689225PubMed
435,344,124Safety and efficacy of salvage surgery for non-small cell lung cancer: a retrospective study of 46 patients from four Keio-affiliated hospitals.Gen Thorac Cardiovasc Surg2022https://conductscience.org/library/papers/35344124PubMed
531,220,530Trimodality vs Chemoradiation and Salvage Resection in cN2 Stage IIIA Non-Small Cell Lung Cancer.Semin Thorac Cardiovasc Surg2020https://conductscience.org/library/papers/31220530PubMed
632,473,131Salvage Lung Resections After Definitive Chemoradiotherapy: A Safe and Effective Oncologic Option.Ann Thorac Surg2020https://conductscience.org/library/papers/32473131PubMed
734,128,318Salvage surgery following downstaging of advanced non-small cell lung cancer by targeted therapy.Thorac Cancer2021https://conductscience.org/library/papers/34128318PubMed
834,985,920First-Line Immunotherapy for Non-Small-Cell Lung Cancer.J Clin Oncol2022https://conductscience.org/library/papers/34985920PubMed
934,379,252ASO Author Reflections: A Simple Method to Predict Risk Factors of Complications After Pneumonectomy.Ann Surg Oncol2022https://conductscience.org/library/papers/34379252PubMed
1035,304,712Safety of salvage lung resection after immunotherapy for unresectable non-small cell lung cancer.Gen Thorac Cardiovasc Surg2022https://conductscience.org/library/papers/35304712PubMed

1 to 10 of 27

See all 27 references

Cited by4

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 6 citations.

PMIDTitleJournalYearIn PapersSource
42,176,153Clinical predictors of pathological response after immunotherapy in salvage surgery for non-small cell lung cancer: a supplementary analysis of the CReGYT-05 immune checkpoint inhibitor-salvage study.Gen Thorac Cardiovasc Surg2026https://conductscience.org/library/papers/42176153PubMed
41,774,364ASO Author Reflections: Salvage Surgery in the Immunotherapy Era: A New Paradigm for Advanced Non-Small Cell Lung Cancer.Ann Surg Oncol2026https://conductscience.org/library/papers/41774364PubMed
41,746,575Efficacy and Safety of Salvage Surgery After Immunotherapy in Non-small Cell Lung Cancer: A Multi-institutional Retrospective Study.Ann Surg Oncol2026https://conductscience.org/library/papers/41746575PubMed
40,722,617Salvage Pulmonary Resection After Immune Checkpoint or Tyrosine Kinase Inhibitor Therapy for Initially Unresectable Non-Small-Cell Lung Cancer: A Systematic Review.Biomedicines2025https://conductscience.org/library/papers/40722617PubMed

Genes0

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

None in this release.

Drugs0

The drugs whose trials, in the Pipelines release, list the paper.

None in this release.

Data0

The data bank entries PubMed's record names. Trial numbers are under Trials.

None in this release.

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/39296459

GET https://conductscience.org/api/papers/v1/39296459/references?page=2

API referenceFor AI assistants